Common Questions About Chronic Prostatitis

Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American family physician 2016-02, Vol.93 (4), p.290-296
Hauptverfasser: Holt, James D., MD, Garrett, W. Allan, MD, Mccurry, Tyler K., DO, Teichman, Joel M.H., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 296
container_issue 4
container_start_page 290
container_title American family physician
container_volume 93
creator Holt, James D., MD
Garrett, W. Allan, MD
Mccurry, Tyler K., DO
Teichman, Joel M.H., MD
description Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropathic pain. Chronic prostatitis must be differentiated from other causes of chronic pelvic pain, such as interstitial cystitis/bladder pain syndrome and pelvic floor dysfunction; prostate and bladder cancers; benign prostatic hyperplasia; urolithiasis; and other causes of dysuria, urinary frequency, and nocturia. The National Institutes of Health divides prostatitis into four syndromes: acute bacterial prostatitis, chronic bacterial prostatitis (CBP), chronic nonbacterial prostatitis (CNP)/chronic pelvic pain syndrome (CPPS), and asymptomatic inflammatory prostatitis. CBP and CNP/CPPS both lead to pelvic pain and lower urinary tract symptoms. CBP presents as recurrent urinary tract infections with the same organism identified on repeated cultures; it responds to a prolonged course of an antibiotic that adequately penetrates the prostate, if the urine culture suggests sensitivity. If four to six weeks of antibiotic therapy is effective but symptoms recur, another course may be prescribed, perhaps in combination with alpha blockers or nonopioid analgesics. CNP/CPPS, accounting for more than 90% of chronic prostatitis cases, presents as prostatic pain lasting at least three months without consistent culture results. Weak evidence supports the use of alpha blockers, pain medications, and a four- to six-week course of antibiotics for the treatment of CNP/CPPS. Patients may also be referred to a psychologist experienced in managing chronic pain. Experts on this condition recommend a combination of treatments tailored to the patient's phenotypic presentation. Urology referral should be considered when appropriate treatment is ineffective. Additional treatments include pelvic floor physical therapy, phytotherapy, and pain management techniques. The UPOINT (urinary, psychosocial, organ-specific, infection, neurologic/systemic, tenderness) approach summarizes the various factors that may contribute to presentation and can guide treatment.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1769980915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002838X16300454</els_id><sourcerecordid>1769980915</sourcerecordid><originalsourceid>FETCH-LOGICAL-e294t-db0700008ae94c9b7ab505f599d0ff2b2afb4f60626c0c4d9ec280c5f8afb3fb3</originalsourceid><addsrcrecordid>eNpdkNtKxDAQhoMo7lp9BSl4I0JhmjZpciMsxRMsqKjgXUjTBLO2zZq0wr69WXb1QhgYhvnm8P8HaJ6TAmdACRyiOQDgjBXsfYZOQljFsiI5P0YzTDmmLKdzdFW7vndD-jzpMFo3hHTRuGlM6w_vBqvSJ-_CKEc72nCKjozsgj7b5wS93d681vfZ8vHuoV4sM415OWZtA1W8BExqXireVLIhQAzhvAVjcIOlaUpDgWKqQJUt1wozUMSw2ChiJOhyt3ft3df2LdHboHTXyUG7KYi8opwz4FFpgi7-oSs3-SF-J3BJSlwwUuWROt9TU9PrVqy97aXfiF8XInC9A3SU9W21F6qzUb3sPvVGh7-duQhYgHjZ-rq1NY4CxDvFDzkpbUU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454238571</pqid></control><display><type>article</type><title>Common Questions About Chronic Prostatitis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Holt, James D., MD ; Garrett, W. Allan, MD ; Mccurry, Tyler K., DO ; Teichman, Joel M.H., MD</creator><creatorcontrib>Holt, James D., MD ; Garrett, W. Allan, MD ; Mccurry, Tyler K., DO ; Teichman, Joel M.H., MD</creatorcontrib><description>Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropathic pain. Chronic prostatitis must be differentiated from other causes of chronic pelvic pain, such as interstitial cystitis/bladder pain syndrome and pelvic floor dysfunction; prostate and bladder cancers; benign prostatic hyperplasia; urolithiasis; and other causes of dysuria, urinary frequency, and nocturia. The National Institutes of Health divides prostatitis into four syndromes: acute bacterial prostatitis, chronic bacterial prostatitis (CBP), chronic nonbacterial prostatitis (CNP)/chronic pelvic pain syndrome (CPPS), and asymptomatic inflammatory prostatitis. CBP and CNP/CPPS both lead to pelvic pain and lower urinary tract symptoms. CBP presents as recurrent urinary tract infections with the same organism identified on repeated cultures; it responds to a prolonged course of an antibiotic that adequately penetrates the prostate, if the urine culture suggests sensitivity. If four to six weeks of antibiotic therapy is effective but symptoms recur, another course may be prescribed, perhaps in combination with alpha blockers or nonopioid analgesics. CNP/CPPS, accounting for more than 90% of chronic prostatitis cases, presents as prostatic pain lasting at least three months without consistent culture results. Weak evidence supports the use of alpha blockers, pain medications, and a four- to six-week course of antibiotics for the treatment of CNP/CPPS. Patients may also be referred to a psychologist experienced in managing chronic pain. Experts on this condition recommend a combination of treatments tailored to the patient's phenotypic presentation. Urology referral should be considered when appropriate treatment is ineffective. Additional treatments include pelvic floor physical therapy, phytotherapy, and pain management techniques. The UPOINT (urinary, psychosocial, organ-specific, infection, neurologic/systemic, tenderness) approach summarizes the various factors that may contribute to presentation and can guide treatment.</description><identifier>ISSN: 0002-838X</identifier><identifier>EISSN: 1532-0650</identifier><identifier>PMID: 26926816</identifier><language>eng</language><publisher>United States: American Academy of Family Physicians</publisher><subject>Abscesses ; Adrenergic alpha-Antagonists - therapeutic use ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Bacteria ; Bacterial infections ; Bladder cancer ; Cancer therapies ; Chlamydia ; Chronic Disease ; Diagnostic Imaging ; Disease ; Humans ; Hyperplasia ; Infections ; Internal Medicine ; Irritable bowel syndrome ; Laboratories ; Male ; Pain ; Pain Measurement - methods ; Patients ; Pelvic Pain - diagnosis ; Pelvic Pain - etiology ; Pelvic Pain - therapy ; Physical Therapy Modalities ; Prostate cancer ; Prostatitis - complications ; Prostatitis - diagnosis ; Prostatitis - therapy ; Quality of life ; Risk Factors ; Urinalysis ; Urine ; Urogenital system</subject><ispartof>American family physician, 2016-02, Vol.93 (4), p.290-296</ispartof><rights>American Family Physician</rights><rights>Copyright American Academy of Family Physicians Feb 15, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26926816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holt, James D., MD</creatorcontrib><creatorcontrib>Garrett, W. Allan, MD</creatorcontrib><creatorcontrib>Mccurry, Tyler K., DO</creatorcontrib><creatorcontrib>Teichman, Joel M.H., MD</creatorcontrib><title>Common Questions About Chronic Prostatitis</title><title>American family physician</title><addtitle>Am Fam Physician</addtitle><description>Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropathic pain. Chronic prostatitis must be differentiated from other causes of chronic pelvic pain, such as interstitial cystitis/bladder pain syndrome and pelvic floor dysfunction; prostate and bladder cancers; benign prostatic hyperplasia; urolithiasis; and other causes of dysuria, urinary frequency, and nocturia. The National Institutes of Health divides prostatitis into four syndromes: acute bacterial prostatitis, chronic bacterial prostatitis (CBP), chronic nonbacterial prostatitis (CNP)/chronic pelvic pain syndrome (CPPS), and asymptomatic inflammatory prostatitis. CBP and CNP/CPPS both lead to pelvic pain and lower urinary tract symptoms. CBP presents as recurrent urinary tract infections with the same organism identified on repeated cultures; it responds to a prolonged course of an antibiotic that adequately penetrates the prostate, if the urine culture suggests sensitivity. If four to six weeks of antibiotic therapy is effective but symptoms recur, another course may be prescribed, perhaps in combination with alpha blockers or nonopioid analgesics. CNP/CPPS, accounting for more than 90% of chronic prostatitis cases, presents as prostatic pain lasting at least three months without consistent culture results. Weak evidence supports the use of alpha blockers, pain medications, and a four- to six-week course of antibiotics for the treatment of CNP/CPPS. Patients may also be referred to a psychologist experienced in managing chronic pain. Experts on this condition recommend a combination of treatments tailored to the patient's phenotypic presentation. Urology referral should be considered when appropriate treatment is ineffective. Additional treatments include pelvic floor physical therapy, phytotherapy, and pain management techniques. The UPOINT (urinary, psychosocial, organ-specific, infection, neurologic/systemic, tenderness) approach summarizes the various factors that may contribute to presentation and can guide treatment.</description><subject>Abscesses</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>Chlamydia</subject><subject>Chronic Disease</subject><subject>Diagnostic Imaging</subject><subject>Disease</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Infections</subject><subject>Internal Medicine</subject><subject>Irritable bowel syndrome</subject><subject>Laboratories</subject><subject>Male</subject><subject>Pain</subject><subject>Pain Measurement - methods</subject><subject>Patients</subject><subject>Pelvic Pain - diagnosis</subject><subject>Pelvic Pain - etiology</subject><subject>Pelvic Pain - therapy</subject><subject>Physical Therapy Modalities</subject><subject>Prostate cancer</subject><subject>Prostatitis - complications</subject><subject>Prostatitis - diagnosis</subject><subject>Prostatitis - therapy</subject><subject>Quality of life</subject><subject>Risk Factors</subject><subject>Urinalysis</subject><subject>Urine</subject><subject>Urogenital system</subject><issn>0002-838X</issn><issn>1532-0650</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkNtKxDAQhoMo7lp9BSl4I0JhmjZpciMsxRMsqKjgXUjTBLO2zZq0wr69WXb1QhgYhvnm8P8HaJ6TAmdACRyiOQDgjBXsfYZOQljFsiI5P0YzTDmmLKdzdFW7vndD-jzpMFo3hHTRuGlM6w_vBqvSJ-_CKEc72nCKjozsgj7b5wS93d681vfZ8vHuoV4sM415OWZtA1W8BExqXireVLIhQAzhvAVjcIOlaUpDgWKqQJUt1wozUMSw2ChiJOhyt3ft3df2LdHboHTXyUG7KYi8opwz4FFpgi7-oSs3-SF-J3BJSlwwUuWROt9TU9PrVqy97aXfiF8XInC9A3SU9W21F6qzUb3sPvVGh7-duQhYgHjZ-rq1NY4CxDvFDzkpbUU</recordid><startdate>20160215</startdate><enddate>20160215</enddate><creator>Holt, James D., MD</creator><creator>Garrett, W. Allan, MD</creator><creator>Mccurry, Tyler K., DO</creator><creator>Teichman, Joel M.H., MD</creator><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160215</creationdate><title>Common Questions About Chronic Prostatitis</title><author>Holt, James D., MD ; Garrett, W. Allan, MD ; Mccurry, Tyler K., DO ; Teichman, Joel M.H., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e294t-db0700008ae94c9b7ab505f599d0ff2b2afb4f60626c0c4d9ec280c5f8afb3fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Abscesses</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>Chlamydia</topic><topic>Chronic Disease</topic><topic>Diagnostic Imaging</topic><topic>Disease</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Infections</topic><topic>Internal Medicine</topic><topic>Irritable bowel syndrome</topic><topic>Laboratories</topic><topic>Male</topic><topic>Pain</topic><topic>Pain Measurement - methods</topic><topic>Patients</topic><topic>Pelvic Pain - diagnosis</topic><topic>Pelvic Pain - etiology</topic><topic>Pelvic Pain - therapy</topic><topic>Physical Therapy Modalities</topic><topic>Prostate cancer</topic><topic>Prostatitis - complications</topic><topic>Prostatitis - diagnosis</topic><topic>Prostatitis - therapy</topic><topic>Quality of life</topic><topic>Risk Factors</topic><topic>Urinalysis</topic><topic>Urine</topic><topic>Urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holt, James D., MD</creatorcontrib><creatorcontrib>Garrett, W. Allan, MD</creatorcontrib><creatorcontrib>Mccurry, Tyler K., DO</creatorcontrib><creatorcontrib>Teichman, Joel M.H., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holt, James D., MD</au><au>Garrett, W. Allan, MD</au><au>Mccurry, Tyler K., DO</au><au>Teichman, Joel M.H., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Common Questions About Chronic Prostatitis</atitle><jtitle>American family physician</jtitle><addtitle>Am Fam Physician</addtitle><date>2016-02-15</date><risdate>2016</risdate><volume>93</volume><issue>4</issue><spage>290</spage><epage>296</epage><pages>290-296</pages><issn>0002-838X</issn><eissn>1532-0650</eissn><abstract>Chronic prostatitis is relatively common, with a lifetime prevalence of 1.8% to 8.2%. Risk factors include conditions that facilitate introduction of bacteria into the urethra and prostate (which also predispose the patient to urinary tract infections) and conditions that can lead to chronic neuropathic pain. Chronic prostatitis must be differentiated from other causes of chronic pelvic pain, such as interstitial cystitis/bladder pain syndrome and pelvic floor dysfunction; prostate and bladder cancers; benign prostatic hyperplasia; urolithiasis; and other causes of dysuria, urinary frequency, and nocturia. The National Institutes of Health divides prostatitis into four syndromes: acute bacterial prostatitis, chronic bacterial prostatitis (CBP), chronic nonbacterial prostatitis (CNP)/chronic pelvic pain syndrome (CPPS), and asymptomatic inflammatory prostatitis. CBP and CNP/CPPS both lead to pelvic pain and lower urinary tract symptoms. CBP presents as recurrent urinary tract infections with the same organism identified on repeated cultures; it responds to a prolonged course of an antibiotic that adequately penetrates the prostate, if the urine culture suggests sensitivity. If four to six weeks of antibiotic therapy is effective but symptoms recur, another course may be prescribed, perhaps in combination with alpha blockers or nonopioid analgesics. CNP/CPPS, accounting for more than 90% of chronic prostatitis cases, presents as prostatic pain lasting at least three months without consistent culture results. Weak evidence supports the use of alpha blockers, pain medications, and a four- to six-week course of antibiotics for the treatment of CNP/CPPS. Patients may also be referred to a psychologist experienced in managing chronic pain. Experts on this condition recommend a combination of treatments tailored to the patient's phenotypic presentation. Urology referral should be considered when appropriate treatment is ineffective. Additional treatments include pelvic floor physical therapy, phytotherapy, and pain management techniques. The UPOINT (urinary, psychosocial, organ-specific, infection, neurologic/systemic, tenderness) approach summarizes the various factors that may contribute to presentation and can guide treatment.</abstract><cop>United States</cop><pub>American Academy of Family Physicians</pub><pmid>26926816</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-838X
ispartof American family physician, 2016-02, Vol.93 (4), p.290-296
issn 0002-838X
1532-0650
language eng
recordid cdi_proquest_miscellaneous_1769980915
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Abscesses
Adrenergic alpha-Antagonists - therapeutic use
Anti-Bacterial Agents - therapeutic use
Antibiotics
Bacteria
Bacterial infections
Bladder cancer
Cancer therapies
Chlamydia
Chronic Disease
Diagnostic Imaging
Disease
Humans
Hyperplasia
Infections
Internal Medicine
Irritable bowel syndrome
Laboratories
Male
Pain
Pain Measurement - methods
Patients
Pelvic Pain - diagnosis
Pelvic Pain - etiology
Pelvic Pain - therapy
Physical Therapy Modalities
Prostate cancer
Prostatitis - complications
Prostatitis - diagnosis
Prostatitis - therapy
Quality of life
Risk Factors
Urinalysis
Urine
Urogenital system
title Common Questions About Chronic Prostatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T06%3A57%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Common%20Questions%20About%20Chronic%20Prostatitis&rft.jtitle=American%20family%20physician&rft.au=Holt,%20James%20D.,%20MD&rft.date=2016-02-15&rft.volume=93&rft.issue=4&rft.spage=290&rft.epage=296&rft.pages=290-296&rft.issn=0002-838X&rft.eissn=1532-0650&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1769980915%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454238571&rft_id=info:pmid/26926816&rft_els_id=1_s2_0_S0002838X16300454&rfr_iscdi=true